GlaxoSmithKline receives new EU approval for flu vaccine Fluarix Tetra

GlaxoSmithKline has received European regulatory approval for its flu vaccine Fluarix Tetra in an expanded indication.

The vaccine will now be made available for the treatment of adults and children from the age of six months for the prevention of disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine.

It has also been approved to be concomitantly administered with pneumococcal polysaccharide vaccines in people aged 50 years and above, with the same dose of Fluarix Tetra covering all eligible patients.

Studies have shown that vaccinating children against influenza may induce herd immunity against influenza for adults aged 65 years and older, meaning this new approval could offer significant public health benefits.

Thomas Breuer, chief medical officer at GlaxoSmithKline Vaccines, said: "By expanding our indication for Fluarix Tetra in Europe, we can help ensure parents have the ability to help protect their children even earlier against the flu."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.